$ENLV News

Enlivex To Feature Extended 3-Month And 6-Months Clinical Data In Knee Osteoarthritis Phase Iia Trial At EULAR European Congress Of Rheumatology

EnLivex Doses First Patient In Its Phase 2b Clinical Trial Of Allocetra For Treatment Of Patients With Moderate-to-Severe Age-Related Symptomatic Primary Knee Osteoarthritis

Enlivex advances Allocetra while expanding into prediction markets

Enlivex Treasury Holdings Of RAIN Tokens Reaches 78,819,756,062 Tokens Valued At $567M

Enlivex Treasury Holdings Of RAIN Tokens Reaches 78,819,756,062 Tokens Valued At $567M

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

Enlivex Files Prospectus Related To Resale Of Up To 23.33M Shares By Selling Shareholder

Enlivex Announces Second Regulatory Approval From Danish Medicines Agency For Global Phase 2b Trial Of Allocetra In Age-Related Primary Knee Osteoarthritis

H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook

Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares

HC Wainwright & Co. Maintains Buy on Enlivex, Raises Price Target to $20

Enlivex Therapeutics Q4 Earnings Call Highlights

CORRECTION: Enlivex Therapeutics Q4 Adj. EPS $(0.20) Misses $(0.01) Estimate. Adj EPS Excludes Change In Fair Value Of Digital Assets Purchase Option

Enlivex Announces $21M Convertible Debt Financing At a 264% Premium With A Single Investor; Approves $20M Buyback Pending Regulatory Approval; Also Exercises Option To Acquire 3.03B RAIN Tokens At 62% Discount For $10M

Enlivex Receives First FDA Approval For Phase2b Trial Of Allocetra For Age-Related Osteoarthritis

Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Enlivex Therapeutics announces new listing of RAIN token on Kraken

Enlivex Therapeutics Says Primary Treasury Asset RAIN Token Listed On Kraken Exchange

RedChip Spotlights the Future of Finance at Fintech & Digital Asset Treasury Strategy (DATS) Virtual Investor Conference on February 4

Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq